UNIVERSITY OF MELBOURNE

Collins BioMicrosystems Laboratory introduces Dynamic Interface Printing (DIP), a 3D bioprinting method using acoustic waves to guide cells into precise configurations, producing complex human tissues in seconds—350 times faster than traditional bioprinters. DIP enhances cell viability and structural accuracy, with potential applications in regenerative medicine and disease modeling.

University of Melbourne researchers developed a 3D bioprinter using sound waves and light to create complex cellular structures in seconds, addressing traditional bioprinting's limitations of speed and cell viability. This Dynamic Interface Printing (DIP) system, which leverages an air-liquid boundary, enables rapid, precise cell positioning and can handle a variety of materials, offering potential in cancer research, pharmaceutical development, and regenerative medicine.

University of Melbourne's biomedical engineers unveiled a 3D bioprinter replicating human tissues with high precision and speed, aiming to reshape drug discovery, especially for cancer research, by closely mimicking diverse tissues. The innovative system uses acoustic waves to position cells, drastically improving print speed and cell positioning, crucial for accurate tissue representation. This method completes prints 350 times faster than conventional approaches, directly into lab plates, enhancing cell survival rates and bridging the gap between lab research and clinical applications.

University of Melbourne engineers developed a bioprinter using dynamic interface printing, which leverages acoustically modulated air–liquid boundaries to rapidly fabricate centimeter-scale 3D structures in seconds, significantly improving cell positioning and tissue replication for pharmaceutical therapy development and reducing the need for animal testing.

Australia's University of Melbourne launches Doherty Clinical Trials, the country's first facility for human challenge trials, aiming to streamline clinical trial regulations.

University of Melbourne engineers developed a 3D bioprinter using acoustic waves for precise cell positioning, significantly speeding up the process (350x faster) and improving cell survival, aiming to advance drug discovery and reduce animal testing.

Cas13bt3 and sgRNA plasmids delivered via AAV reduced VEGFA mRNA and protein in human retinal organoids and VEGF-transgenic mice with minimal off-target effects. Single-cell RNA sequencing confirmed high specificity in retinal pigment epithelium cells. The study, led by Satheesh Kumar and Guei-Sheung Liu, was published in PNAS.

John Gorman, a pioneer in treating Rh disease in the 1960s, has been awarded Australia's highest honor, an AC, for his eminent service to humanity. His breakthrough in using anti-D serum, known as RhoGAM, has almost eliminated Rh disease in developed countries, saving countless lives. Gorman's work continues with the World Initiative for Rh disease Eradication, aiming to provide anti-D to Rh-negative mothers globally.

Aumolertinib significantly improves progression-free survival in stage III EGFR-mutated NSCLC after chemoradiotherapy (30.4 months vs 3.8 months; HR = 0.200; P < .0001).

Babies exposed to polluted air in Melbourne had higher rates of peanut allergy, but not egg allergy or eczema, according to a study by Dr. Diego Lopez. The study, involving nearly 5,300 children, linked increased air pollution to higher odds of peanut allergy, with no similar impact on other immune-based conditions. The findings were published in the 'Journal of Allergy and Clinical Immunology: In Practice'.